- Email: [email protected]
P2.04-024 Thymic Epithelial Tumors and Radiotherapy Results
January 2017
Abstracts
genes and treatment targets in TET. Masaoka stage and histological subtypes predict the survival of TET. Keywords: next-generation sequencing, Thymic epithelial tumors, Gene mutation
Prognosis,
P2.04-024 Thymic Epithelial Tumors and Radiotherapy Results Topic: Thymic Malignancies Clinical and Translational Sureyya Sarihan,1 Ahmet Sami Bayram,2 Cengiz Gebitekin,3 Omer Yerci,4 Deniz Sigirli5 1 Radiation Oncology, Uludag University, Faculty of Medicine, Bursa/Turkey, 2Uludag University, Faculty of Medicine, Bursa/Turkey, 3Thoracic Surgery, Uludag University, Faculty of Medicine, Bursa/Turkey, 4Pathology, Uludag University, Faculty of Medicine, Bursa/Turkey, 5 Biostatistics, Uludag University, Faculty of Medicine, Bursa/Turkey Background: Thymic epithelial tumors (TET) treated with radiotherapy (RT) was evaluated for treatment outcomes and prognostic factors on survival. Methods: Between October 1995 and December 2013, 31 patients were treated. The median age was 44 (range: 19-83). There were 25 thymoma, 4 thymic carcinoma (TC) and 2 thymic neuroendocrin carcinoma (NEC). The incidence were found 13%, 39%, 39% and 9% for Masaoka stage I-II-III and IV, and 3%, 16%, 61%, 13% and 6%, for WHO type A-AB-B-C and NEC, respectively. Eighteen patients (58%) underwent R0 resection. Median RT dose was 5400 cGy (range: 1620-6596). Seven patients received a median of 6 cycles (range: 1-6) cisplatin-based adjuvant and 4 patients received weekly 60-70 mg/m2 paclitaxel or 2-3 cycles standard chemotherapy concurrently. According to prognostic risk stratification including Masaoka staging and WHO classification, cases were divided to good (n: 10), moderate (n: 9) and poor (n: 12) risk groups. Survival was calculated from diagnosis. Results: In January 2016, 22 cases lived with median 51.5 months (range: 2-170.5) follow-up. Recurrences were observed 9 (29%) of patients median 29.5 months (range: 6.5-105). Local control, mean overall (OS) and disease-free survival (DFS) rates for all patients, were 86%, 119 months (range: 94-144) and 116 months (range: 89-144), respectively. Local control were 100%, 89% and 75% for good, moderate and poor risk groups, respectively (p¼0.08). There were a significant differences for Masaoka stage (I-II vs III-IV, p ¼ 0.001, p
S1011
<0.001), R0 resection (present vs absent, p ¼ 0.06, p ¼ 0.05), histology (thymoma vs TC, p ¼ 0.02, p ¼ 0.01) and prognostic risk groups (good vs moderate vs poor, p ¼ 0.003, p ¼ 0.004) in terms of OS and DFS, respectively. Conclusion: In our study, prognostic risk stratification was seen to be an important predictor for survival. The patients with TC was stage III-IV at diagnosis in moderate and poor risk groups indirectly and survival rates was found to be less than thymoma. Keywords: Thymic epithelial tumors, Radiotherapy, survival, prognostic groups
P2.04-025 Recombinant Human Endostatin and/or Cisplatin in Treatment of Malignant Hydrothorax and Ascites: A Multicenter Randomized Study Topic: Esophageal Cancer and Other Malignancies Shukui Qin,1 Ying Cheng,2 Qinghe Tan,3 Jingwang Bi,4 Liwei Wang,5 Bing Hu,6 Jianhua Shi,7 Guoping Sun,8 Yuxian Bai,9 Min Tao,10 Weijian Guo,11 Bing Lu,12 Jun Liang,13 Helong Zhang14 1PLA Cancer Center, The Affiliated 81 Hospital of PLA, Nanjing/China, 2Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun/ China, 3Nantong Cancer Hospital, Nantong/China, 4Jinan Military General Hospital, Jinan/China, 5Shanghai First Hospital, Shanghai/China, 6Anhui Provincial Hospital, Hefei/China, 7Linyi Cancer Hospital, Linyi/China, 8The First Affiliated Hospital of Anhui Medical University, Hefei/China, 9Harbin Medical University Cancer Hospital, Harbin/China, 10The First Affiliated Hospital of Suzhou University, Suzhou/China, 11Fudan University Shanghai Cancer Center, Shanghai/China, 12Shanghai Pulmonary Hospital, Shanghai/China, 13Beijing Cancer Hospital, Beijing/China, 14Tangdu Hospital, Xian/China Background: To evaluate the clinical efficacy and safety of intra-pleural injection of recombinant human endostatin (Endostar) and/or Cisplatin in treatment of malignant hydrothorax and ascites. Methods: A total of 317 patients with more than moderate amount of pericardial effusion malignant hydrothorax and ascites were randomly divided into group A (Endostar group, n¼105), group B (Cisplatin group, n¼104) and group C (Endostar combined Cisplatin, n¼108). After puncture and drainage, Endostar, 45 mg per time by intrathoracic injection or 60 mg per time by intraperitoneal injection was performed in Group A. Cisplatin, 40 mg per time by intra-pleural injection on
Abstracts
genes and treatment targets in TET. Masaoka stage and histological subtypes predict the survival of TET. Keywords: next-generation sequencing, Thymic epithelial tumors, Gene mutation
Prognosis,
P2.04-024 Thymic Epithelial Tumors and Radiotherapy Results Topic: Thymic Malignancies Clinical and Translational Sureyya Sarihan,1 Ahmet Sami Bayram,2 Cengiz Gebitekin,3 Omer Yerci,4 Deniz Sigirli5 1 Radiation Oncology, Uludag University, Faculty of Medicine, Bursa/Turkey, 2Uludag University, Faculty of Medicine, Bursa/Turkey, 3Thoracic Surgery, Uludag University, Faculty of Medicine, Bursa/Turkey, 4Pathology, Uludag University, Faculty of Medicine, Bursa/Turkey, 5 Biostatistics, Uludag University, Faculty of Medicine, Bursa/Turkey Background: Thymic epithelial tumors (TET) treated with radiotherapy (RT) was evaluated for treatment outcomes and prognostic factors on survival. Methods: Between October 1995 and December 2013, 31 patients were treated. The median age was 44 (range: 19-83). There were 25 thymoma, 4 thymic carcinoma (TC) and 2 thymic neuroendocrin carcinoma (NEC). The incidence were found 13%, 39%, 39% and 9% for Masaoka stage I-II-III and IV, and 3%, 16%, 61%, 13% and 6%, for WHO type A-AB-B-C and NEC, respectively. Eighteen patients (58%) underwent R0 resection. Median RT dose was 5400 cGy (range: 1620-6596). Seven patients received a median of 6 cycles (range: 1-6) cisplatin-based adjuvant and 4 patients received weekly 60-70 mg/m2 paclitaxel or 2-3 cycles standard chemotherapy concurrently. According to prognostic risk stratification including Masaoka staging and WHO classification, cases were divided to good (n: 10), moderate (n: 9) and poor (n: 12) risk groups. Survival was calculated from diagnosis. Results: In January 2016, 22 cases lived with median 51.5 months (range: 2-170.5) follow-up. Recurrences were observed 9 (29%) of patients median 29.5 months (range: 6.5-105). Local control, mean overall (OS) and disease-free survival (DFS) rates for all patients, were 86%, 119 months (range: 94-144) and 116 months (range: 89-144), respectively. Local control were 100%, 89% and 75% for good, moderate and poor risk groups, respectively (p¼0.08). There were a significant differences for Masaoka stage (I-II vs III-IV, p ¼ 0.001, p
S1011
<0.001), R0 resection (present vs absent, p ¼ 0.06, p ¼ 0.05), histology (thymoma vs TC, p ¼ 0.02, p ¼ 0.01) and prognostic risk groups (good vs moderate vs poor, p ¼ 0.003, p ¼ 0.004) in terms of OS and DFS, respectively. Conclusion: In our study, prognostic risk stratification was seen to be an important predictor for survival. The patients with TC was stage III-IV at diagnosis in moderate and poor risk groups indirectly and survival rates was found to be less than thymoma. Keywords: Thymic epithelial tumors, Radiotherapy, survival, prognostic groups
P2.04-025 Recombinant Human Endostatin and/or Cisplatin in Treatment of Malignant Hydrothorax and Ascites: A Multicenter Randomized Study Topic: Esophageal Cancer and Other Malignancies Shukui Qin,1 Ying Cheng,2 Qinghe Tan,3 Jingwang Bi,4 Liwei Wang,5 Bing Hu,6 Jianhua Shi,7 Guoping Sun,8 Yuxian Bai,9 Min Tao,10 Weijian Guo,11 Bing Lu,12 Jun Liang,13 Helong Zhang14 1PLA Cancer Center, The Affiliated 81 Hospital of PLA, Nanjing/China, 2Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun/ China, 3Nantong Cancer Hospital, Nantong/China, 4Jinan Military General Hospital, Jinan/China, 5Shanghai First Hospital, Shanghai/China, 6Anhui Provincial Hospital, Hefei/China, 7Linyi Cancer Hospital, Linyi/China, 8The First Affiliated Hospital of Anhui Medical University, Hefei/China, 9Harbin Medical University Cancer Hospital, Harbin/China, 10The First Affiliated Hospital of Suzhou University, Suzhou/China, 11Fudan University Shanghai Cancer Center, Shanghai/China, 12Shanghai Pulmonary Hospital, Shanghai/China, 13Beijing Cancer Hospital, Beijing/China, 14Tangdu Hospital, Xian/China Background: To evaluate the clinical efficacy and safety of intra-pleural injection of recombinant human endostatin (Endostar) and/or Cisplatin in treatment of malignant hydrothorax and ascites. Methods: A total of 317 patients with more than moderate amount of pericardial effusion malignant hydrothorax and ascites were randomly divided into group A (Endostar group, n¼105), group B (Cisplatin group, n¼104) and group C (Endostar combined Cisplatin, n¼108). After puncture and drainage, Endostar, 45 mg per time by intrathoracic injection or 60 mg per time by intraperitoneal injection was performed in Group A. Cisplatin, 40 mg per time by intra-pleural injection on